Drug persistence with rivaroxaban therapy in atrial fibrillation patients—results from the Dresden non-interventional oral anticoagulation registry

AIMS: Worldwide, rivaroxaban is increasingly used for stroke prevention in atrial fibrillation (SPAF) but little is known about the rates of or reasons for rivaroxaban discontinuations in daily care. Using data from a prospective, non-interventional oral anticoagulation (NOAC) registry, we analysed...

Descripción completa

Detalles Bibliográficos
Autores principales: Beyer-Westendorf, Jan, Förster, Kati, Ebertz, Franziska, Gelbricht, Vera, Schreier, Thomas, Göbelt, Maria, Michalski, Franziska, Endig, Heike, Sahin, Kurtulus, Tittl, Luise, Weiss, Norbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381834/
https://www.ncbi.nlm.nih.gov/pubmed/25694537
http://dx.doi.org/10.1093/europace/euu319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381834/
https://www.ncbi.nlm.nih.gov/pubmed/25694537
http://dx.doi.org/10.1093/europace/euu319

Ejemplares similares